## Fabio Arnesano

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6414630/publications.pdf

Version: 2024-02-01

95 papers

4,078 citations

35 h-index 61 g-index

105 all docs

 $\begin{array}{c} 105 \\ \\ \text{docs citations} \end{array}$ 

105 times ranked 4876 citing authors

#	Article	IF	CITATIONS
1	Interaction of Copper Trafficking Proteins with the Platinum Anticancer Drug Kiteplatin. ChemMedChem, 2022, 17, .	1.6	3
2	<sup>19</sup> F NMR Allows the Investigation of the Fate of Platinum(IV) Prodrugs in Physiological Conditions. Angewandte Chemie - International Edition, 2022, 61, .	7.2	25
3	<sup>19</sup> F NMR Allows the Investigation of the Fate of Platinum(IV) Prodrugs in Physiological Conditions. Angewandte Chemie, 2022, 134, .	1.6	8
4	Tryptophan regulates <i>Drosophila</i> zinc stores. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2117807119.	3.3	19
5	Multinuclear Metal-Binding Ability of the N-Terminal Region of Human Copper Transporter Ctr1: Dependence Upon pH and Metal Oxidation State. Frontiers in Molecular Biosciences, 2022, 9, .	1.6	6
6	Improvement of Kiteplatin Efficacy by a Benzoato Pt(IV) Prodrug Suitable for Oral Administration. International Journal of Molecular Sciences, 2022, 23, 7081.	1.8	9
7	The zinc proteome of SARS-CoV-2. Metallomics, 2022, 14, .	1.0	6
8	A Bioâ€Conjugated Fullerene as a Subcellularâ€Targeted and Multifaceted Phototheranostic Agent. Advanced Functional Materials, 2021, 31, 2101527.	7.8	22
9	NMR spectroscopy to study the fate of metallodrugs in cells. Current Opinion in Chemical Biology, 2021, 61, 214-226.	2.8	7
10	Interference between copper transport systems and platinum drugs. Seminars in Cancer Biology, 2021, 76, 173-188.	4.3	38
11	A Contribution to the Harmonization of Non-targeted NMR Methods for Data-Driven Food Authenticity Assessment. Food Analytical Methods, 2020, 13, 530-541.	1.3	21
12	Mechanistic and Structural Basis for Inhibition of Copper Trafficking by Platinum Anticancer Drugs. Journal of the American Chemical Society, 2019, 141, 12109-12120.	6.6	24
13	Oxidation of Human Copper Chaperone Atox1 and Disulfide Bond Cleavage by Cisplatin and Glutathione. International Journal of Molecular Sciences, 2019, 20, 4390.	1.8	3
14	Cisplatin reacts with histone H1 and the adduct forms a ternary complex with DNA. Metallomics, 2019, 11, 556-564.	1.0	14
15	Reaction of Histone H1 with <i>trans</i> -Platinum Complexes and the Effect on DNA Platination. Inorganic Chemistry, 2019, 58, 6485-6494.	1.9	2
16	Concentration-dependent effects of mercury and lead on AÎ <sup>2</sup> 42: possible implications for Alzheimer's disease. European Biophysics Journal, 2019, 48, 173-187.	1.2	34
17	Differential Reactivity of Metal Binding Domains of Copper ATPases towards Cisplatin and Colocalization of Copper and Platinum. Chemistry - A European Journal, 2018, 24, 8999-9003.	1.7	10
18	Tetrathiomolybdate inhibits the reaction of cisplatin with human copper chaperone Atox1. Metallomics, 2018, 10, 745-750.	1.0	10

#	Article	IF	CITATIONS
19	Aggregation Pathways of Nativeâ€Like Ubiquitin Promoted by Singleâ€Point Mutation, Metal Ion Concentration, and Dielectric Constant of the Medium. Chemistry - A European Journal, 2018, 24, 4140-4148.	1.7	1
20	Effect of i>in vivo i>post-translational modifications of the HMGB1 protein upon binding to platinated DNA: a molecular simulation study. Nucleic Acids Research, 2018, 46, 11687-11697.	6.5	15
21	Structural Elucidation of Cisplatin and Hydrated <i>cis</i> i>-Diammineplatinum(II) Complex Conjugated with Cyanocobalamin by Liquid Chromatography with Electrospray Ionization–Mass Spectrometry and Multistage Mass Spectrometry. ACS Omega, 2018, 3, 12914-12922.	1.6	6
22	Monitoring Interactions Inside Cells by Advanced Spectroscopies: Overview of Copper Transporters and Cisplatin. Current Medicinal Chemistry, 2018, 25, 462-477.	1.2	15
23	Platinum drugs, copper transporters and copper chelators. Coordination Chemistry Reviews, 2018, 374, 254-260.	9.5	31
24	Effect of cisplatin on the transport activity of P <sub>II</sub> -type ATPases. Metallomics, 2017, 9, 960-968.	1.0	12
25	Cyanocobalamin conjugates of cisplatin and diaminocyclohexane-platinum(ii): matrix-assisted laser desorption ionization mass spectrometry characterization using 4-chloro-α-cyanocinnamic acid as the matrix. RSC Advances, 2017, 7, 53658-53666.	1.7	10
26	Copper Homeostasis in Humans and Bacteria. , 2017, , .		0
27	Probing the interaction between cisplatin and the therapeutic monoclonal antibody trastuzumab. RSC Advances, 2016, 6, 29229-29236.	1.7	4
28	Activation of Platinum(IV) Prodrugs by Cytochrome <i>c</i> and Characterization of the Protein Binding Sites. Molecular Pharmaceutics, 2016, 13, 3216-3223.	2.3	30
29	Duplications of an iron–sulphur tripeptide leads to the formation of a protoferredoxin. Chemical Communications, 2016, 52, 13456-13459.	2.2	35
30	Oxaliplatin Binding to Human Copper Chaperone Atox1 and Protein Dimerization. Inorganic Chemistry, 2016, 55, 6563-6573.	1.9	17
31	Silver and gold nanoparticles produced by pulsed laser ablation in liquid to investigate their interaction with Ubiquitin. Applied Surface Science, 2016, 374, 297-304.	3.1	40
32	Copper binding to naturally occurring, lactam form of angiogenin differs from that to recombinant protein, affecting their activity. Metallomics, 2016, 8, 118-124.	1.0	20
33	The Effects of Chronic Lifelong Activation of the AHR Pathway by Industrial Chemical Pollutants on Female Human Reproduction. PLoS ONE, 2016, 11, e0152181.	1.1	23
34	Performance Assessment in Fingerprinting and Multi Component Quantitative NMR Analyses. Analytical Chemistry, 2015, 87, 6709-6717.	3.2	45
35	Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs. Journal of Inorganic Biochemistry, 2015, 150, 1-8.	1.5	44
36	PREFACE: Contributions to platinum bioinorganic chemistry and beyond honoring Professor Giovanni Natile on the occasion of his 70th birthday. Journal of Inorganic Biochemistry, 2015, 153, 204-205.	1.5	0

#	Article	IF	CITATIONS
37	Computational metallomics of the anticancer drug cisplatin. Journal of Inorganic Biochemistry, 2015, 153, 231-238.	1.5	20
38	The reaction of a platinated methionine motif of CTR1 with cysteine and histidine is dependent upon the type of precursor platinum complex. Journal of Inorganic Biochemistry, 2015, 153, 239-246.	1.5	7
39	Intranasal delivery of dopamine to the striatum using glycol chitosan/sulfobutylether-β-cyclodextrin based nanoparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 94, 180-193.	2.0	81
40	Effect of chirality in platinum drugs. Coordination Chemistry Reviews, 2015, 284, 286-297.	9.5	50
41	Amyloid Transition of Ubiquitin on Silver Nanoparticles Produced by Pulsed Laser Ablation in Liquid as a Function of Stabilizer and Singleâ€Point Mutations. Chemistry - A European Journal, 2014, 20, 10745-10751.	1.7	24
42	Structural Biology of Cisplatin Complexes with Cellular Targets: The Adduct with Human Copper Chaperone Atox1 in Aqueous Solution. Chemistry - A European Journal, 2014, 20, 11719-11725.	1.7	14
43	Translocation of Platinum Anticancer Drugs by Human Copper ATPases ATP7A and ATP7B. Angewandte Chemie - International Edition, 2014, 53, 1297-1301.	7.2	79
44	Heavy metals toxicity: effect of cadmium ions on amyloid beta protein 1–42. Possible implications for Alzheimer's disease. BioMetals, 2014, 27, 371-388.	1.8	75
45	Platination of the copper transporter ATP7A involved in anticancer drug resistance. Dalton Transactions, 2014, 43, 12085.	1.6	29
46	Investigation on the influence of (Z)-3-(2-(3-chlorophenyl)hydrazono)-5,6-dihydroxyindolin-2-one (PT2) on $\hat{l}^2$ -amyloid( $1\hat{a}$ e"40) aggregation and toxicity. Archives of Biochemistry and Biophysics, 2014, 560, 73-82.	1.4	12
47	Molecular Recognition of Platinated DNA from Chromosomal HMGB1. Journal of Chemical Theory and Computation, 2014, 10, 3578-3584.	2.3	12
48	C <sub>60</sub> @Lysozyme: Direct Observation by Nuclear Magnetic Resonance of a 1:1 Fullerene Protein Adduct. ACS Nano, 2014, 8, 1871-1877.	7.3	70
49	Cisplatin handover between copper transporters: the effect of reducing agents. Journal of Biological Inorganic Chemistry, 2014, 19, 705-714.	1.1	13
50	CHAPTER 15. Platinum. 2-Oxoglutarate-Dependent Oxygenases, 2014, , 429-460.	0.8	3
51	Structure of matrix metalloproteinase-3 with a platinum-based inhibitor. Chemical Communications, 2013, 49, 5492.	2.2	11
52	Chemical and cellular investigations of trans-ammine-pyridine-dichlorido-platinum(II), the likely metabolite of the antitumor active cis-diammine-pyridine-chorido-platinum(II). Journal of Inorganic Biochemistry, 2013, 129, 15-22.	1.5	14
53	Conformational Selection of Ubiquitin Quaternary Structures Driven by Zinc Ions. Chemistry - A European Journal, 2013, 19, 15480-15484.	1.7	5
54	An Updated View of Cisplatin Transport. European Journal of Inorganic Chemistry, 2013, 2013, 2701-2711.	1.0	63

#	Article	IF	Citations
55	Structural Determinants of Cisplatin and Transplatin Binding to the Met-Rich Motif of Ctr1: A Computational Spectroscopy Approach. Journal of Chemical Theory and Computation, 2012, 8, 2912-2920.	2.3	27
56	Effect of Thioethers on DNA Platination bytrans-Platinum Complexes. Inorganic Chemistry, 2011, 50, 8168-8176.	1.9	17
57	Probing the Interaction of Cisplatin with the Human Copper Chaperone Atox1 by Solution and In-Cell NMR Spectroscopy. Journal of the American Chemical Society, 2011, 133, 18361-18369.	6.6	114
58	Crystallographic Analysis of Metal″on Binding to Human Ubiquitin. Chemistry - A European Journal, 2011, 17, 1569-1578.	1.7	25
59	Unusual Interstrand Pt( <i>S,S</i> â€diaminocyclohexane)â€GG Crosslink Formed by Rearrangement of a Classical Intrastrand Crosslink Within a DNA Duplex. Chemistry - an Asian Journal, 2010, 5, 244-247.	1.7	5
60	Analysis by phage display selection and site-directed retromutagenesis of the Mustard Trypsin Inhibitor 2 reactive site. Journal of Plant Physiology, 2010, 167, 1507-1511.	1.6	4
61	Methionine Can Favor DNA Platination by <i>trans</i> >â€Coordinated Platinum Antitumor Drugs. Angewandte Chemie - International Edition, 2009, 48, 8497-8500.	7.2	50
62	Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA. Coordination Chemistry Reviews, 2009, 253, 2070-2081.	9.5	251
63	Mechanistic Insight into the Inhibition of Matrix Metalloproteinases by Platinum Substratesâ€. Journal of Medicinal Chemistry, 2009, 52, 7847-7855.	2.9	28
64	Copper-Triggered Aggregation of Ubiquitin. PLoS ONE, 2009, 4, e7052.	1.1	46
65	Structural probing of Zn(ii), Cd(ii) and Hg(ii) binding to human ubiquitin. Chemical Communications, 2008, , 5960.	2.2	24
66	"Platinum on the road": Interactions of antitumoral cisplatin with proteins. Pure and Applied Chemistry, 2008, 80, 2715-2725.	0.9	59
67	Insights into the Molecular Mechanisms of Protein Platination from a Case Study:  The Reaction of Anticancer Platinum(II) Iminoethers with Horse Heart Cytochrome c. Biochemistry, 2007, 46, 12220-12230.	1.2	51
68	Platinum Complexes Can Inhibit Matrix Metalloproteinase Activity: Platinumâ°Diethyl[(methylsulfinyl)methyl]phosphonate Complexes as Inhibitors of Matrix Metalloproteinases 2, 3, 9, and 12. Journal of Medicinal Chemistry, 2007, 50, 3434-3441.	2.9	47
69	Ubiquitin Stability and the Lys 63‣inked Polyubiquitination Site Are Compromised on Copper Binding. Angewandte Chemie - International Edition, 2007, 46, 7993-7995.	7.2	36
70	Interaction between Platinum Complexes and a Methionine Motif Found in Copper Transport Proteins. Angewandte Chemie - International Edition, 2007, 46, 9062-9064.	7.2	91
71	An Italian contribution to structural genomics: Understanding metalloproteins. Coordination Chemistry Reviews, 2006, 250, 1419-1450.	9.5	14
72	Folding Studies of Cox17 Reveal an Important Interplay of Cysteine Oxidation and Copper Binding. Structure, 2005, 13, 713-722.	1.6	121

#	Article	IF	Citations
73	Structural Interplay between Calcium(II) and Copper(II) Binding to S100A13 Protein. Angewandte Chemie - International Edition, 2005, 44, 6341-6344.	7.2	38
74	NMR structures of paramagnetic metalloproteins. Quarterly Reviews of Biophysics, 2005, 38, 167-219.	2.4	84
75	Ortholog Search of Proteins Involved in Copper Delivery to CytochromecOxidase and Functional Analysis of Paralogs and Gene Neighbors by Genomic Context. Journal of Proteome Research, 2005, 4, 63-70.	1.8	40
76	A Docking Approach to the Study of Copper Trafficking Proteins. Structure, 2004, 12, 669-676.	1.6	56
77	Perspectives in Inorganic Structural Genomics: A Trafficking Route for Copper. European Journal of Inorganic Chemistry, 2004, 2004, 1583-1593.	1.0	77
78	Perspectives in Inorganic Structural Genomics: A Trafficking Route for Copper. ChemInform, 2004, 35, no.	0.1	0
79	The Unusually Stable Quaternary Structure of Human Cu,Zn-Superoxide Dismutase 1 Is Controlled by Both Metal Occupancy and Disulfide Status. Journal of Biological Chemistry, 2004, 279, 47998-48003.	1.6	223
80	A Strategy for the NMR Characterization of Type II Copper(II) Proteins:Â the Case of the Copper Trafficking Protein CopC fromPseudomonasSyringae. Journal of the American Chemical Society, 2003, 125, 7200-7208.	6.6	98
81	A redox switch in CopC: An intriguing copper trafficking protein that binds copper(I) and copper(II) at different sites. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 3814-3819.	3.3	173
82	The Evolutionarily Conserved Trimeric Structure of CutA1 Proteins Suggests a Role in Signal Transduction. Journal of Biological Chemistry, 2003, 278, 45999-46006.	1.6	52
83	Solution Structure and Characterization of the Heme Chaperone CcmE. Biochemistry, 2002, 41, 13587-13594.	1.2	47
84	Metallochaperones and Metal-Transporting ATPases: A Comparative Analysis of Sequences and Structures. Genome Research, 2002, 12, 255-271.	2.4	232
85	Solution Structure of CopC. Structure, 2002, 10, 1337-1347.	1.6	104
86	Structural genomics on metalloproteins. Gene Function & Disease, 2002, 3, 49-55.	0.3	1
87	Characterization of the Binding Interface between the Copper Chaperone Atx1 and the First Cytosolic Domain of Ccc2 ATPase. Journal of Biological Chemistry, 2001, 276, 41365-41376.	1.6	132
88	Solution Structure of the Cu(I) and Apo Forms of the Yeast Metallochaperone, Atx1â€,‡. Biochemistry, 2001, 40, 1528-1539.	1.2	172
89	The auto-orientation in high magnetic fields of oxidized cytochrome b562 as source of constraints for solution structure determination. Journal of Biomolecular NMR, 2000, 17, 295-304.	1.6	25
90	Structural Consequences ofb- toc-type Heme Conversion in OxidizedEscherichia coliCytochromeb562â€,‡. Biochemistry, 2000, 39, 1499-1514.	1.2	46

#	Article	IF	CITATIONS
91	Monitoring Mobility in the Early Steps of Unfolding: The Case of Oxidized Cytochromeb5in the Presence of 2 M Guanidinium Chlorideâ€. Biochemistry, 2000, 39, 7117-7130.	1.2	18
92	Solution structure of the B form of oxidized rat microsomal cytochromeâ€fb5and backbone dynamics via15N rotating-frame NMR-relaxation measurements. FEBS Journal, 1999, 260, 347-354.	0.2	28
93	The Solution Structure of Oxidized Escherichia coli Cytochrome b562,. Biochemistry, 1999, 38, 8657-8670.	1.2	82
94	Solution Structure of Oxidized Rat Microsomal Cytochrome b5 in the Presence of 2 M Guanidinium Chloride:  Monitoring the Early Steps in Protein Unfolding,. Biochemistry, 1998, 37, 17082-17092.	1.2	19
95	The Solution Structure of Oxidized Rat Microsomal Cytochromeb5â€,‡. Biochemistry, 1998, 37, 173-184.	1.2	86